DR. JAMES NORMAN LOWDER, MD
Medical Laboratory at Del Sol Ave, Pleasanton, CA
License number
California G47304
Category
Medical Laboratory
Type
Clinical Medical Laboratory
Address
Address
559 Del Sol Ave, Pleasanton, CA 94566
Phone
(925) 640-4852
Personal information
See more information about JAMES NORMAN LOWDER at radaris.comName
Address
Phone
603 Macarthur Dr, Daly City, CA 94015
5976 Dunsmuir Ave, Dunsmuir, CA 96025
40953 Acacia Ave, Hemet, CA 92544
4314 E 4Th St, Long Beach, CA 90814
800 The Mark Ln UNIT 2803, San Diego, CA 92101
Professional information
Nasopharyngeal Wash Collection Device
US Patent:
5643202, Jul 1, 1997
Filed:
Sep 14, 1995
Appl. No.:
8/527970
Inventors:
Stefan Gravenstein - Madison WI
Peter Alan Shult - Stoughton WI
Barbara Ann Miller - Madison WI
James Norman Lowder - Pleasanton CA
Peter Alan Shult - Stoughton WI
Barbara Ann Miller - Madison WI
James Norman Lowder - Pleasanton CA
Assignee:
Specollector, Inc. - Stoughton WI
Becton Dickinson and Company - Franklin Lakes NJ
Becton Dickinson and Company - Franklin Lakes NJ
International Classification:
A61M 3100
US Classification:
604 54
Abstract:
A self-contained device for rapid and repetitive delivery and collection of a fluid. The device includes a container having resilient walls and a lower portion in which the walls converge to form an inverted, generally elliptical frustum that pools the fluid stored in the container. The device also includes a nozzle having a funnel-shaped opening which facilitates discharge and collection of the fluid.
Methods Of Treatment Of Ulcerative Colitis And Crohn's Disease With Anti-Cd3 Antibodies
US Patent:
2007022, Sep 27, 2007
Filed:
Mar 1, 2007
Appl. No.:
11/713465
Inventors:
Ian Walters - Swampscott MA, US
James Lowder - Pleasanton CA, US
James Lowder - Pleasanton CA, US
Assignee:
PDL BioPharma, Inc. - Fremont CA
International Classification:
A61K 39/395
US Classification:
424133100, 424130100
Abstract:
The present invention provides a method of treating autoimmune diseases. In particular, it provides a method for the treatment of ulcerative colitis or Crohn's disease comprising administering to a subject a therapeutically effective amount of a pharmaceutical formulation comprising an antibody, wherein said antibody binds to CD3.